

Foundation Medicine, Inc.  
Form SC14D9C  
June 19, 2018

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14D-9**

**(RULE 14d-101)**

**SOLICITATION/RECOMMENDATION STATEMENT UNDER  
SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Foundation Medicine, Inc.**

(Name of Subject Company)

**Foundation Medicine, Inc.**

(Name of Person(s) Filing Statement)

**Common Stock, par value \$0.0001 per Share**

(Title of Class of Securities)

**350456100**

(CUSIP Number of Class of Securities)

**Robert W. Hesslein**

**Senior Vice President and General Counsel**

**150 Second Street**

**Cambridge MA, 02141**

**(617) 418-2200**

(Name, Address and Telephone Number of Person Authorized to Receive Notices  
and Communications on Behalf of the Person(s) Filing Statement)

With copies to:

**Stuart M. Cable**

**Lisa R. Haddad**

**Goodwin Procter LLP**

**100 Northern Avenue**

**Boston, MA 02210**

**(617) 570-1000**

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01 and 7.01 of the Current Report on Form 8-K filed by Foundation Medicine, Inc. on June 19, 2018 (including all exhibits attached thereto) is incorporated herein by reference.